The global gastroesophageal reflux disease therapeutics market size is expected to reach USD 5.95 billion by 2030, expanding at a CAGR of 1.76% from 2023 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.
Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.
Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.
Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.
Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.
Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.
Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.
Gastroesophageal Reflux Disease Therapeutics Market Report Highlights
- Antacids segment dominated the gastroesophageal reflux disease treatment market in 2021 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach
- Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
- Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD
- North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients
Table of Contents
Chapter 1 Gastroesophageal Reflux Disease Therapeutics Market: Methodology And Scope1.1 Market Segmentation
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.11 List Of Abbreviations
Chapter 2 Gastroesophageal Reflux Disease Therapeutics Market: Executive Summary
2.1 Gastroesophageal Reflux Disease Therapeutics Market: Market Outlook
2.1.1 Market Summary
Chapter 3 Gastroesophageal Reflux Disease Therapeutics Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Low Success Rates Of Gerd Management Devices, Leading To Higher Adoption Of Therapeutics
3.3.1.2 Rising Prevalence Of Gerd And Other Gastrointestinal Disorders
3.3.1.3 Rising Trend For Self Medication And Presence Of Strong Product Pipeline
3.3.2 Market Restraint Analysis
3.3.2.1 Patent expiry of blockbuster drugs prescribed
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter’s
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
3.7.1 New Product Launch
3.7.2 Acquisition
3.7.3 Expansion
3.7.4 Partnerships
3.7.5 Marketing & Promotions
Chapter 4 Gastroesophageal Reflux Disease Therapeutics Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Company Categorization
4.2.1 Innovators
4.2.1.1 Market Differentiators
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.3.3 Key Company Market Share Analysis, 2022
4.4 Public Companies
4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map
Chapter 5 Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis
5.1 Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Movement Analysis
5.2 Antacids
5.2.1 Antacids Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.3 H2 Receptor Blockers
5.3.1 H2 Receptor Blockers Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.4 Proton Pump Inhibitors (Ppis)
5.4.1 Proton Pump Inhibitors (Ppis) Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.5 Pro-Kinetic Agents
5.5.1 Pro-Kinetic Agents Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Gastroesophageal Reflux Disease Therapeutics Market: Regional Business Analysis
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Dashboard
6.4 Regional Market Snapshot
6.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
6.5.1 North America
6.5.2 Europe
6.5.3 Asia Pacific
6.5.4 Latin America
6.5.5 MEA
6.6 Market Size, & Forecasts, Trend Analysis, 2021 To 2030
6.7 North America
6.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.7.2 U.S.
6.7.2.1 U.S. Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.7.2.2 Key Country Dynamics
6.7.2.3 Regulatory Framework
6.7.2.4 Competitive Scenario
6.7.2.5 Recent Developments
6.7.2.6 Investments Scenario
6.7.3 Canada
6.7.3.1 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.7.3.2 Key country Dynamics
6.7.3.3 Regulatory Framework
6.7.3.4 Competitive Scenario
6.7.3.5 Recent Developments
6.7.3.6 Investments Scenario
6.8 Europe
6.8.1 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.2 UK
6.8.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.2.2 Key country Dynamics
6.8.2.3 Regulatory Framework
6.8.2.4 Competitive Scenario
6.8.2.5 Recent Developments
6.8.2.6 Investments Scenario
6.8.3 Germany
6.8.3.1 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.3.2 Key Country Dynamics
6.8.3.3 Regulatory Framework
6.8.3.4 Competitive Scenario
6.8.3.5 Recent Developments
6.8.3.6 Investments Scenario
6.8.4 Spain
6.8.4.1 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.4.2 Key Country Dynamics
6.8.4.3 Regulatory Framework
6.8.4.4 Competitive Scenario
6.8.4.5 Recent Developments
6.8.4.6 Investments Scenario
6.8.5 France
6.8.5.1 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.5.2 Key Country Dynamics
6.8.5.3 Regulatory Framework
6.8.5.4 Competitive Scenario
6.8.5.5 Recent Developments
6.8.5.6 Investments Scenario
6.8.6 Italy
6.8.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.6.2 Key Country Dynamics
6.8.6.3 Regulatory Framework
6.8.6.4 Competitive Scenario
6.8.6.5 Recent Developments
6.8.6.6 Investments Scenario
6.8.7 Denmark
6.8.7.1 Denmark Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.7.2 Key Country Dynamics
6.8.7.3 Regulatory Framework
6.8.7.4 Competitive Scenario
6.8.7.5 Recent Developments
6.8.7.6 Investments Scenario
6.8.8 Sweden
6.8.8.1 Sweden Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.8.2 Key Country Dynamics
6.8.8.3 Regulatory Framework
6.8.8.4 Competitive Scenario
6.8.8.5 Recent Developments
6.8.8.6 Investments Scenario
6.8.9 Norway
6.8.9.1 Norway Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.8.9.2 Key Country Dynamics
6.8.9.3 Regulatory Framework
6.8.9.4 Competitive Scenario
6.8.9.5 Recent Developments
6.8.9.6 Investments Scenario
6.9 Asia Pacific
6.9.1 Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.2 Japan
6.9.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.2.2 Key Country Dynamics
6.9.2.3 Regulatory Framework
6.9.2.4 Competitive Scenario
6.9.2.5 Recent Developments
6.9.2.6 Investments Scenario
6.9.3 China
6.9.3.1 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.3.2 Key Country Dynamics
6.9.3.3 Regulatory Framework
6.9.3.4 Competitive Scenario
6.9.3.5 Recent Developments
6.9.3.6 Investments Scenario
6.9.4 India
6.9.4.1 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.4.2 Key Country Dynamics
6.9.4.3 Regulatory Framework
6.9.4.4 Competitive Scenario
6.9.4.5 Recent Developments
6.9.4.6 Investments Scenario
6.9.5 South Korea
6.9.5.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.5.2 Key Country Dynamics
6.9.5.3 Regulatory Framework
6.9.5.4 Competitive Scenario
6.9.5.5 Recent Developments
6.9.5.6 Investments Scenario
6.9.6 Thailand
6.9.6.1 Thailand Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.6.2 Key Country Dynamics
6.9.6.3 Regulatory Framework
6.9.6.4 Competitive Scenario
6.9.6.5 Recent Developments
6.9.6.6 Investments Scenario
6.9.7 Australia
6.9.7.1 Australia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.9.7.2 Key Country Dynamics
6.9.7.3 Regulatory Framework
6.9.7.4 Competitive Scenario
6.9.7.5 Recent Developments
6.9.7.6 Investments Scenario
6.10 Latin America
6.10.1 Latin America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.10.2 Brazil
6.10.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.10.2.2 Key Country Dynamics
6.10.2.3 Regulatory Framework
6.10.2.4 Competitive Scenario
6.10.2.5 Recent Developments
6.10.2.6 Investments Scenario
6.10.3 Mexico
6.10.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.10.3.2 Key Country Dynamics
6.10.3.3 Regulatory Framework
6.10.3.4 Competitive Scenario
6.10.3.5 Recent Developments
6.10.3.6 Investments Scenario
6.10.4 Argentina
6.10.4.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.10.4.2 Key Country Dynamics
6.10.4.3 Regulatory Framework
6.10.4.4 Competitive Scenario
6.10.4.5 Recent Developments
6.10.4.6 Investments Scenario
6.11 MEA
6.11.1 MEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.11.2 South Africa
6.11.2.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.11.2.2 Key Country Dynamics
6.11.2.3 Regulatory Framework
6.11.2.4 Competitive Scenario
6.11.2.5 Recent Developments
6.11.2.6 Investments Scenario
6.11.3 Saudi Arabia
6.11.3.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.11.3.2 Key Country Dynamics
6.11.3.3 Regulatory Framework
6.11.3.4 Competitive Scenario
6.11.3.5 Recent Developments
6.11.3.6 Investments Scenario
6.11.4 Uae
6.11.4.1 Uae Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.11.4.2 Key Country Dynamics
6.11.4.3 Regulatory Framework
6.11.4.4 Competitive Scenario
6.11.4.5 Recent Developments
6.11.4.6 Investments Scenario
6.11.5 Kuwait
6.11.5.1 Kuwait Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2030 (USD Million)
6.11.5.2 Key Country Dynamics
6.11.5.3 Regulatory Framework
6.11.5.4 Competitive Scenario
6.11.5.5 Recent Developments
6.11.5.6 Investments Scenario
Chapter 7 Gastroesophageal Reflux Disease Therapeutics Market: Company Profiling
7.1 Company Profiles
7.1.1 Astrazeneca
7.1.1.1 Company Overview
7.1.1.2 Financial Performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 Eisai Co., Ltd.
7.1.2.1 Company Overview
7.1.2.2 Financial Performance
7.1.2.3 Product Benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 Gsk Plc.
7.1.3.1 Company Overview
7.1.3.2 Financial Performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 Takeda Pharmaceutical Company Limited.
7.1.4.1 Company Overview
7.1.4.2 Financial Performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 Ironwood Pharmaceuticals, Inc.
7.1.5.1 Company Overview
7.1.5.2 Financial Performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 Johnson & Johnson Services, Inc.
7.1.6.1 Company Overview
7.1.6.2 Financial Performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic Initiatives
7.1.7 Sfj Pharmaceuticals
7.1.7.1 Company Overview
7.1.7.2 Financial Performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 Sebela Pharmaceuticals
7.1.8.1 Company Overview
7.1.8.2 Financial Performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 Phathom Pharmaceuticals, Inc.
7.1.9.1 Company Overview
7.1.9.2 Financial Performance
7.1.9.3 Product Benchmarking
7.1.9.4 Strategic Initiatives
7.1.10 Camber Pharmaceuticals, Inc.
7.1.10.1 Company Overview
7.1.10.2 Financial Performance
7.1.10.3 Product Benchmarking
7.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Gastroesophageal Reflux Disease Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 6 North America Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 7 North America Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 8 U.S. Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 9 Canada Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 10 Europe Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 11 Europe Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 12 UK Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 13 Germany Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 14 France Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 15 Spain Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 16 Italy Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 17 Denmark Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 18 Sweden Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 19 Norway Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 20 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 21 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 22 Japan Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 23 China Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 24 Australia Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 25 Thailand Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 26 India Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 27 South Korea Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 28 Latin America Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 29 Latin America Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 30 Mexico Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 31 Brazil Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 32 Argentina Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 33 MEA Gastroesophageal Reflux Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 34 MEA Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 35 South Africa Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 36 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 37 UAE Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
Table 38 Kuwait Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Gastroesophageal Reflux Disease Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Gastroesophageal reflux disease therapeutics market: Drug type outlook and key takeaways
Fig. 16 Gastroesophageal reflux disease therapeutics market: Drug type movement analysis & market share 2022 & 2030
Fig. 17 Antacids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 H2 receptors inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Proton pump inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Pro-kinetic agents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Regional Marketplace: Key Takeaways
Fig. 22 Regional Outlook, 2022 & 2030
Fig. 23 Regional Market Dashboard
Fig. 24 Regional Market Place: Key Takeaways
Fig. 25 North America, SWOT Analysis
Fig. 26 Europe, SWOT Analysis
Fig. 27 Asia Pacific, SWOT Analysis
Fig. 28 Latin America, SWOT Analysis
Fig. 29 MEA, SWOT Analysis
Fig. 30 North America
Fig. 31 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 32 U.S.
Fig. 33 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 34 Canada
Fig. 35 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 36 Europe
Fig. 37 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 38 UK
Fig. 39 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 40 Germany
Fig. 41 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 42 France
Fig. 43 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 44 Italy
Fig. 45 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 46 Spain
Fig. 47 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 48 Denmark
Fig. 49 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 50 Sweden
Fig. 51 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 52 Norway
Fig. 53 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 54 Asia Pacific
Fig. 55 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 56 Japan
Fig. 57 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 58 China
Fig. 59 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 60 India
Fig. 61 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 62 Australia
Fig. 63 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 64 Thailand
Fig. 65 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 66 South Korea
Fig. 67 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 68 Latin America
Fig. 69 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 70 Brazil
Fig. 71 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 72 Mexico
Fig. 73 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 74 Argentina
Fig. 75 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 76 MEA
Fig. 77 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 78 South Africa
Fig. 79 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 80 Saudi Arabia
Fig. 81 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 82 UAE
Fig. 83 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 84 Kuwait
Fig. 85 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 86 Strategy Mapping
Companies Mentioned
- Astrazeneca
- Eisai Co., Ltd.
- Gsk Plc.
- Takeda Pharmaceutical Company Limited.
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Sfj Pharmaceuticals
- Sebela Pharmaceuticals
- Phathom Pharmaceuticals, Inc.
- Camber Pharmaceuticals, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5.18 Billion |
| Forecasted Market Value ( USD | $ 5.95 Billion |
| Compound Annual Growth Rate | 1.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
